HC Wainwright Boosts BioLineRx (NASDAQ:BLRX) Price Target to $21.00

BioLineRx (NASDAQ:BLRX) had its target price boosted by research analysts at HC Wainwright from $19.00 to $21.00 in a research note issued on Friday, FlyOnTheWall reports.

Separately, StockNews.com upgraded BioLineRx to a “sell” rating in a research report on Monday, September 4th.

BioLineRx Trading Up 6.0 %

Shares of NASDAQ:BLRX opened at $1.76 on Friday. BioLineRx has a 52-week low of $0.55 and a 52-week high of $2.53. The stock has a market cap of $108.29 million, a price-to-earnings ratio of -2.55 and a beta of 1.80. The company has a quick ratio of 2.79, a current ratio of 2.79 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average price of $1.61 and a 200-day moving average price of $1.35.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Wednesday, August 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.14). During the same period in the previous year, the firm posted ($0.16) earnings per share. Equities analysts predict that BioLineRx will post -0.83 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its position in BioLineRx by 278.0% during the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 189,678 shares in the last quarter. LPL Financial LLC increased its position in shares of BioLineRx by 6.4% in the second quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 7,500 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new stake in shares of BioLineRx in the first quarter valued at approximately $178,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of BioLineRx in the first quarter valued at approximately $88,000. 2.01% of the stock is currently owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.